Trial Profile
Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Romidepsin (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; B-cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2020 Results (n=25) assessing efficacy and safety of oral Azacitidine in molecularly annotated PTCL patients published in the Blood
- 05 Nov 2020 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2019 Safety and efficacy results published in the Blood.